| Title: |
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies |
| Authors: |
Jungova, Alexandra 1, #, ⁎; Stork, Martin 2, #; Spicka, Ivan 3; Radocha, Jakub 4; Minarik, Jiri 5; Pavlicek, Petr 6; Mihalyova, Jana 7; Pour, Ludek 2; Straub, Jan 3; Maisnar, Vladimir 4; Pika, Tomas 5; Dekojova, Tereza 1; Soukup, Jan 6; Popkova, Tereza 7; Mensikova, Klara 2; Sedlák, Frantisek 3; Pospiskova, Jana 4; Boichuk, Ivanna 2; Krhovska, Petra 5; Stopka, Tomas 3; Jindra, Pavel 1; Jelínek, Tomas 7; Knechtová, Zdenka 2; Capounova, Vladimira 4; Latal, Vojtech 5; Muronova, Ludmila 7; Heindorfer, Adriana 9; Ullrychova, Jana 10; Sykora, Michal 11; Kessler, Petr 12; Hajek, Roman 7, 8 |
| Source: |
In Clinical Lymphoma, Myeloma and Leukemia April 2026 26(4):e470-e482 |
| Database: |
ScienceDirect |